Breaking News
July 20, 2018 - Understanding triple-negative breast cancer to develop better treatments
July 20, 2018 - Study compares outpatient antibiotic prescribing with traditional medical, retail clinic settings
July 20, 2018 - Immediate Monitoring With ECG Patch Ups A-Fib Diagnosis Rate
July 20, 2018 - Scientists seek to better protect the eye from glaucoma
July 20, 2018 - Football training could improve bone mineral density in prostate cancer patients
July 20, 2018 - Single genetic change in gut bacteria can lead to obesity
July 20, 2018 - Research uncovers new target for therapeutic intervention in breast cancer
July 20, 2018 - WFN to highlight clean air for brain health on World Brain Day 2018
July 20, 2018 - Health Highlights: July 17, 2018
July 20, 2018 - Mom’s marijuana winds up in breast milk
July 20, 2018 - Black men could be healthier if seen by black physicians, new research suggests
July 20, 2018 - Alcoholics have persistent difficulties with emotional communication after long-term abstinence
July 19, 2018 - Researchers unravel how ALL invades the central nervous system
July 19, 2018 - Mother’s microbiome determines offspring’s risk of developing autism
July 19, 2018 - Refining standards of maternal-fetal care
July 19, 2018 - Stitching single cells together any which way you want to
July 19, 2018 - Study identifies RNA molecules that regulate male hormones in prostate cancer
July 19, 2018 - New machine-learning model shows promise in predicting undiagnosed dementia
July 19, 2018 - Sleep supports antioxidant processes, study suggests
July 19, 2018 - MiRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201
July 19, 2018 - Unique brain ‘fingerprint’ can predict drug effectiveness
July 19, 2018 - Life on the border: Struggling to survive in Jordan
July 19, 2018 - CT scans may raise brain tumor risk
July 19, 2018 - Moderate alcohol intake linked with improved male fertility
July 19, 2018 - Alcohol-related cirrhosis mortality on the rise among young adults
July 19, 2018 - Study uncovers new protein complex that shields broken DNA ends
July 19, 2018 - Regular sunscreen use protects young people from melanoma
July 19, 2018 - Using non-invasive brain recordings to characterize activity in deep structures
July 19, 2018 - Mediterranean diet could influence academic performance through effects on sleep quality
July 19, 2018 - Woman’s pregnancy history may be linked to Alzheimer’s disease risk
July 19, 2018 - Study calls for new gold standard in research to treat non-alcoholic steatohepatitis
July 19, 2018 - Cancer patients receiving anti-PD-1 therapies may experience delayed skin reactions
July 19, 2018 - Scientists study adverse effects of carbon, silicon nanotubes and carbon nanofibers
July 19, 2018 - Keck Hospital of USC receives Magnet recognition for excellence in nursing
July 19, 2018 - Scientists identify hidden signals in RNAs that control protein synthesis
July 19, 2018 - Quadrivalent HPV Vaccine Not Tied to Spontaneous Abortion
July 19, 2018 - FDA OKs first drug made to reduce excessive sweating
July 19, 2018 - New Finnish study compares surgical treatment of shoulder impingement syndrome to placebo surgery
July 19, 2018 - New findings do no support caffeine as effective appetite suppressant or weight-loss aid
July 19, 2018 - Kite collaborates with Gadeta to develop novel gamma delta TCR therapies for various cancers
July 19, 2018 - Study evaluates Neoteryx’s VAMS technology for monitoring HbA1c levels of diabetic children
July 19, 2018 - New clinical trial examines use of adrenaline to treat cardiac arrests
July 19, 2018 - Early surgical intervention may improve outcomes for patients with mitral valve disease
July 19, 2018 - Prolonged preoperative opioid use linked to adverse outcomes after total knee and hip arthroplasty
July 19, 2018 - Biophysicists use infrared sensor as new method for drug discovery
July 19, 2018 - Rat study shows negative effects of perinatal exposure to phthalates
July 19, 2018 - Children with disabilities endure long waits for life-changing medical equipment
July 19, 2018 - Ways to stay safe while camping and hiking
July 19, 2018 - People with HIV twice as likely to suffer from heart disease
July 19, 2018 - On-the-Job Stress Relief – Drugs.com MedNews
July 19, 2018 - Compounds found in green tea and wine may block formation of toxic metabolites
July 19, 2018 - Gene regulator associated with protein pileup in exfoliation glaucoma
July 19, 2018 - Trump administration summons immigrant infants
July 19, 2018 - FDA grants approval for first breast cancer drug through ‘Real-Time Oncology Review’
July 19, 2018 - Five tips for men seeking plastic surgery
July 19, 2018 - Researchers discover the reasons why some people get dizzy when hearing certain sounds
July 19, 2018 - Research project investigates snake venom treatment as antibiotic alternative for eye infections
July 19, 2018 - Melanoma could soon be detected using a blood test
July 19, 2018 - Exposure to bright light may have big impact on sleep-related behavior in children
July 19, 2018 - Deleting single gene in gut bacteria affects metabolism, reduces weight gain in mice
July 19, 2018 - New proteomics studies help gain more insights into Alzheimer’s, cancer and listeriosis
July 19, 2018 - Study finds major discrepancies in prescription drug labeling pregnancy information across four countries
July 19, 2018 - Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma
July 19, 2018 - Watching the immune system in action reveals what happens when things goes wrong
July 19, 2018 - Increasing blood sugar levels improves memory and performance in older adults
July 19, 2018 - Connection between self-regulation and obesity appears to be different for girls and boys
July 19, 2018 - Researchers develop new, less destructive method for whitening teeth
July 19, 2018 - Revving up innate control of viral infection requires a three-cell ignition
July 19, 2018 - Inaccurate direct-to-consumer raw genetic data can harm patients, new research suggests
July 19, 2018 - Weight loss surgery is effective under the right situations
July 19, 2018 - BioTek awarded patent for autofocus feature on microplate reader
July 19, 2018 - Low-carb diets reduce stiffness of arteries in women and promote weight loss in men
July 19, 2018 - New review examines cannabinoids’ potential for direct treatment of cancer
July 19, 2018 - Allergic responses may help protect the skin against cancer, research suggests
July 19, 2018 - Inappropriate Prescribing of Abx High in Urgent Care Centers
July 19, 2018 - Many at risk for HIV despite lifesaving pill
July 19, 2018 - Tips for doctors and parents on the harms of marijuana use for teens
July 18, 2018 - Researchers detect presence of IgE antibodies after kidney transplantation
July 18, 2018 - New technique allows researchers to create large scale, personalized bone grafts
July 18, 2018 - Smoking May Boost Atrial Fibrillation Risk
Immunotherapy Combo Active in High-Risk CRC

Immunotherapy Combo Active in High-Risk CRC

image_pdfDownload PDFimage_print

SAN FRANCISCO — More than half of patients with previously treated metastatic colorectal cancer and DNA mismatch repair deficiency (dMMR) had objective responses to the immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy), results of a cohort study showed.

Overall, 65 of 119 patients responded to the combination. The disease control rate (response plus stable disease) was 80%, as reported here at the Gastrointestinal Cancers Symposium.

“Nivolumab plus ipilimumab provided durable clinical benefit in previously treated patients with DNA mismatch repair-deficient, microsatellite instability-high [MSI-H] metastatic colorectal cancer,” said Thierry Andre, MD, of Hopital Saint Antoine and Sorbonne University in Paris. “Median progression-free and overall survival were not reached with a median follow-up of 13 months; 85% of patients remained alive at 1 year.

“Meaningful improvements in quality of life were observed, and the safety of nivolumab and ipilimumab was manageable, with a low rate of discontinuation due to treatment-emergent adverse events.”

The results were published simultaneously in the Journal of Clinical Oncology.

Acknowledging the high response rate and durability of responses with the combination, the invited discussant, Zsofia Kinga Stadler, MD, of Memorial Sloan Kettering Cancer Center in New York City, nonetheless said the combination’s superiority over single-agent nivolumab cannot be assumed: “It’s unclear whether combination immunotherapy provides long-term clinical benefit over anti-PD1 monotherapy. The answer to this will require randomized comparisons of monotherapy versus combination therapy.

“As expected, based on studies of other malignancies, combination therapy with an anti-PD1 and CTLA-4 inhibitor had additional toxicity. Further studies are needed to identify particular subgroups of patients who may benefit from combination therapy.”

Andre reported findings from a study that addressed a small but poor-prognosis subgroup of patients with metastatic colorectal cancer. About 4% of patients have a deficiency in the DNA mismatch repair system, leading to MSI. Multiple studies showed that this subgroup of patients derive less benefit from conventional chemotherapy as compared with patients who have MMR proficient or microsatellite stable disease, Andre noted.

Previously reported results showed that nivolumab monotherapy led to objective responses in a third of patients with dMMR/MSI metastatic colorectal cancer. The responses were durable in many instances. The combination study was conducted in parallel to the monotherapy trial as components of CheckMate-142.

Eligible patients had metastatic colorectal cancer associated with dMMR/MSI-H and exposure to at least one prior line of therapy. In the combination arm, patients received a dose of nivolumab, followed by ipilimumab once every 3 weeks for four doses, and then nivolumab every 2 weeks until disease progression or development of unacceptable toxicity. The primary endpoint was investigator-determined overall response rate.

The 119 patients had a median age of 58; men accounted for 59% of the study population, and all the patients had ECOG 0-1 performance status. Tumor PD-L1 expression was ≥1% in 22% of patients, <1% in 55%, and unknown in 24%. The group included 35 patients (29%) with a clinical history of Lynch syndrome. About a third of patients had received two prior therapies, and 40% had three or more.

The results showed partial responses in 51.3% of patients and complete responses in 3.7%. An additional 31 patients had stable disease during treatment, resulting in a disease control rate of 80%.

“Combination therapy provided a numerically higher objective response rate, including complete responses, and disease control rate, relative to monotherapy during a similar follow-up period,” said Andre.

Almost 80% of patients treated with the combination had some reduction in tumor burden, he added.

Neither objective response rate nor disease control rate differed substantially by PD-L1 expression status, BRAF/KRAS mutation status, or history of Lynch syndrome.

The combination cohort had a median progression-free survival of 76% at 9 months and 71% at 12 months. The overall survival rates at the same time points were 87% and 85%, respectively, with both surpassing the rates observed in the monotherapy groups, Andre reported.

The combination was associated with “statistically significant and clinically meaningful” improvement in quality-of-life measures, and the improvements were maintained for extended treatment periods.

A third of patients had grade 3/4 treatment-emergent adverse events (TRAEs), including serious adverse events in 20% of patients, and leading to treatment discontinuation in 10%. The most commonly reported grade 3/4 TRAE was elevated liver enzymes (AST/ALT) in 7-8% of patients; grade 3/4 diarrhea, fatigue, pruritus, and rash each occurred in 2% of patients.

The study was supported by Bristol-Myers Squibb.

Andre disclosed relationships with Axter, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Lilly, Merck, Novartis, Roche/Genentech, Sanofi, Servier, Xbiotech, Amgen, HalioDX, and Mundipharma.

2018-01-22T15:00:00-0500

Tagged with:

About author

Related Articles